Method for regulating and controlling body immunoreaction through regulation of skin DCs (dendritic cells)/ LCs (Epidermal Langerhans cells) by electric signal to be presented to T cell, and purpose of method

Abstract

The invention discloses a method for regulating and controlling body immunoreaction through the regulation of skin DCs (dendritic cells) / LCs (Epidermal Langerhans cells) by an electric signal to be presented to a T cell. The method comprises the following steps of: cells or skin tissues are put between an electrode A and an electrode B; a direct current power supply is connected between the electrode A and the electrode B; an electric field is formed between the electrode A and the electrode B; current enough to guide and control DCs / LCs cell migration and localization is given; and therefore, the skin DCs / LCs can be regulated through the electric signal to be presented to the T cell to regulate and control the body immunoreaction. The method disclosed by the invention has potential tobe used for preparing a novel vaccine adjuvant, or the method disclosed by the invention and other adjuvants are jointly used for regulating immunoreaction. The method can be used for targeting specific immunomodulators and accurate cancer treatment under a situation that the method is not induced and distributed by a chemical tendency, and common clinical side effects are reduced. Compared with existing common immunomodulators, the method disclosed by the invention has the advantages of a wide adjustable range and low cost, and is favorable for lightening the economic burdens of patients andthe society, and an operation condition of the method can be easily optimized.

Description

technical field [0001] The invention belongs to the technical field of immunity, and in particular relates to a method for regulating the body's immune response by regulating the presentation of skin DCs / LCs to T cells by electrical signals and its application. Background technique [0002] Various physical, chemical and biological factors in the environment can affect skin immunity. Dendritic cells (DCs) are professional antigen-presenting cells that can initiate adaptive immune responses to foreign antigens and maintain T cell tolerance to themselves. The skin and lymphoid organs are the first entry point for microbial pathogens and the initial site of the adaptive immune response, where DCs are most enriched. [0003] Skin DCs include epidermal Langerhans cells (LCs) in the epidermis and dermal DCs (DDCs) in the dermis. Both LCs and DDCs are capable of capturing foreign and self-antigens in vivo and presenting them to naive T cells. ( Tcell). Unlike other antigen-pre...

AI Technical Summary

Problems solved by technology

[0014] Aluminum salt adjuvant: Aluminum salt adjuvant is the most successful and important adjuvant used in human vaccines so far, but there are still shortcomings: it cannot be freeze-dried; antigen adsorption is easily affected by physical and chemical properties, and often occurs in different batches. The immune effect of secondary adjuvants varies greatly, and the quality is unstable; erythema, swelling and induration appear at the injection site; aluminum salts are easy to accumulate in the body, especially in the brain

[0016] AS series adjuvants: AS series adjuvants can cause pain at the injection site, local inflammatory response, and induce inflammatory arthritis, and are prone to uneven mixing with antigens, and the production cost is relatively high

[0017] NB001 nano-adjuvant: This adjuvant can promote the immune enhancement of the body, but its mechanism of action has not yet been elucidated, and there is also the possibility of inducing adverse reactions such as autoimmune diseases and inflammation

[0018] Immunomodulators have been of great value in the prevention and treatment of diseases, but it has been found through clinical application that the currently widely used immunomodulators still inevitably cause some side effects, such as pain at the injection site, erythema and local rash; a small number of patients with intravenous administration Infusion reactions such as headache, fever, and elevated blood pressure may occur; after the use of immunosuppressants such as glucocorticoids, the body is prone to infection due to the suppression of immune function; when the use of immunomodulators artificially interferes with the body's immune response, it is easy to cause immunity. The function is disturbed again and induces new immune-related diseases; in addition, some immunosuppressants can also cause systemic edema, thrombocytopenia, congestive heart failure, low renal function, central nervous system poisoning symptoms, etc.

[0019] In addition, most of the immunomodulators currently in clinical use are expensive, especially imported preparations.

However, patients often need to use immunomodulators for a long time to treat diseases, which is expensive and burdens families and society.

Images